Pyrosequencing for Classification of Human FcγRIIIA Allotypes: A Comparison with PCR-Based Techniques

Molecular Diagnosis and Therapy

Volumn 18, Issue 6, 2014, Pages 665-673

  Matlawska Wasowska, Ksenia ^a   Gale, James M ^b   Nickl, Christian K ^a   Khalili, Parisa ^a   Shirley, Brian ^a   Wilson, Bridget S ^a   Vasef, Mohammad A ^a,b   Winter, Stuart S ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b TRICORE REFERENCE LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CODON; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

ALLELE; ALLOTYPE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PYROSEQUENCING; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CODON; GENETICS; HIGH THROUGHPUT SEQUENCING; PROCEDURES;

ALLELES; CODON; GENOTYPE; GPI-LINKED PROTEINS; HEALTHY VOLUNTEERS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; POLYMERASE CHAIN REACTION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, IGG;

EID: 84916599481     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0120-5     Document Type: Article

References (38)

1. Houot R, Kohrt HE, Marabelle A, Levy R. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol. 2011;32(11):510–6.
2. Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, et al. The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood. 2011;118(17):4657–62.
3. Matlawska-Wasowska K, Ward E, Stevens S, Wang Y, Herbst R, et al. Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies. Leukemia. 2013;27(6):1263–74.
4. Edberg JC, Redecha PB, Salmon JE, Kimberly RP. Human Fc gamma RIII (CD16). Isoforms with distinct allelic expression, extracellular domains, and membrane linkages on polymorphonuclear and natural killer cells. J Immunol. 1989;143(5):1642–9.
5. Hadley AG, Zupanska B, Kumpel BM, Leader KA. The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes. Immunology. 1992;76(3):446–51.
6. Carnahan J, Wang P, Kendall R, Chen C, Hu S, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9(10 Pt 2):3982S–90S.
7. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2010;115(6):1204–13.
8. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87.
9. McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood. 2007;109(3):1185–92.
10. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013;6:1.
11. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005;304(1–2):88–99.
12. Munn DH, McBride M, Cheung NK. Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res. 1991;51(4):1117–23.
13. Ravetch JV, Perussia B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med. 1989;170(2):481–97.
14. Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, et al. The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood. 2002;100(5):1641–7.
15. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940–7.
16. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010;335(1):213–22.
17. Shields RL, Lai J, Keck R, O’Connell LY, Hong K, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–40.
18. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood. 2011;118(12):3347–9.
19. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14.
20. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, et al. Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90(3):1109–14.
21. Dall’Ozzo S, Andres C, Bardos P, Watier H, Thibault G. Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods. 2003;277(1–2):185–92.
22. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Investig. 1997;100(5):1059–70.
23. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005;23(3):474–81.
24. Ge B, Gurd S, Gaudin T, Dore C, Lepage P, et al. Survey of allelic expression using EST mining. Genome Res. 2005;15(11):1584–91.
25. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, et al. Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012;18(12):3478–86.
26. Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64(13):4664–9.
27. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754–8.
28. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108(8):2720–5.
29. Ghesquieres H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood. 2012;120(13):2650–7.
30. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2010;28(2):279–84.
31. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab. Haematologica. 2007;92(8):1127–30.
32. Prochazka V, Papajik T, Gazdova J, Divoka M, Rozmanova S, et al. FcgammaRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma. 2011;58(3):263–70.
33. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010;70(23):9554–61.
34. Cooper N, Stasi R, Cunningham-Rundles S, Cesarman E, McFarland JG, et al. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haematol. 2012;158(4):539–47.
35. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26(11):1789–96.
36. Burchard PR, Malhotra S, Kaur P, Tsongalis GJ. Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay. Cancer Genet. 2013;206(4):130–4.
37. van der Straaten T, Martijn R, el Hajoui T, Baak-Pablo R, Guchelaar HJ. A novel specific pyrosequencing method for genotyping FCGR3A rs396991 without coamplification of homologous gene FCGR3B. Pharmacogenet Genomics. 2013;23(11):631–5.
38. Ellison SL, English CA, Burns MJ, Keer JT. Routes to improving the reliability of low level DNA analysis using real-time PCR. BMC Biotechnol. 2006;6:33.